NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $759,344 | -30.9% | 39,508 | -8.6% | 0.00% | -50.0% |
| Q2 2023 | $1,098,525 | -28.6% | 43,215 | +1.6% | 0.00% | 0.0% |
| Q1 2023 | $1,538,002 | -10.1% | 42,545 | -1.5% | 0.00% | -33.3% |
| Q4 2022 | $1,710,126 | -13.8% | 43,185 | +1.4% | 0.00% | 0.0% |
| Q3 2022 | $1,985,000 | +4.4% | 42,606 | -1.8% | 0.00% | 0.0% |
| Q2 2022 | $1,902,000 | -38.8% | 43,395 | +1.0% | 0.00% | -25.0% |
| Q1 2022 | $3,107,000 | -18.2% | 42,961 | -8.3% | 0.00% | 0.0% |
| Q4 2021 | $3,798,000 | -28.6% | 46,845 | +2.4% | 0.00% | -42.9% |
| Q3 2021 | $5,322,000 | -32.7% | 45,726 | -4.1% | 0.01% | -30.0% |
| Q2 2021 | $7,905,000 | +10.5% | 47,681 | -7.0% | 0.01% | +11.1% |
| Q1 2021 | $7,153,000 | -19.6% | 51,274 | -0.3% | 0.01% | -25.0% |
| Q4 2020 | $8,902,000 | +25.7% | 51,429 | +1.2% | 0.01% | +9.1% |
| Q3 2020 | $7,080,000 | +17.1% | 50,825 | +0.4% | 0.01% | 0.0% |
| Q2 2020 | $6,048,000 | +33.1% | 50,627 | +11.4% | 0.01% | +10.0% |
| Q1 2020 | $4,545,000 | -15.4% | 45,460 | -0.5% | 0.01% | +11.1% |
| Q4 2019 | $5,370,000 | +34.0% | 45,686 | -2.0% | 0.01% | +12.5% |
| Q3 2019 | $4,007,000 | +35.8% | 46,608 | +2.4% | 0.01% | +33.3% |
| Q2 2019 | $2,951,000 | +5.9% | 45,513 | +2.1% | 0.01% | 0.0% |
| Q1 2019 | $2,786,000 | +57.1% | 44,571 | -2.2% | 0.01% | +50.0% |
| Q4 2018 | $1,773,000 | -29.9% | 45,594 | +2.7% | 0.00% | -20.0% |
| Q3 2018 | $2,531,000 | -28.8% | 44,406 | -0.3% | 0.01% | -28.6% |
| Q2 2018 | $3,557,000 | -3.8% | 44,551 | +4.4% | 0.01% | -12.5% |
| Q1 2018 | $3,699,000 | +22.6% | 42,684 | -2.3% | 0.01% | +33.3% |
| Q4 2017 | $3,016,000 | -25.2% | 43,683 | -1.5% | 0.01% | -33.3% |
| Q3 2017 | $4,032,000 | +10.4% | 44,363 | -9.6% | 0.01% | +12.5% |
| Q2 2017 | $3,652,000 | -17.7% | 49,063 | +3.6% | 0.01% | -11.1% |
| Q1 2017 | $4,439,000 | +23.2% | 47,374 | -4.4% | 0.01% | +28.6% |
| Q4 2016 | $3,602,000 | -32.2% | 49,574 | -2.6% | 0.01% | -36.4% |
| Q3 2016 | $5,311,000 | +42.7% | 50,874 | +0.8% | 0.01% | +37.5% |
| Q2 2016 | $3,723,000 | +87.5% | 50,474 | +43.0% | 0.01% | +100.0% |
| Q1 2016 | $1,986,000 | -4.8% | 35,307 | +14.3% | 0.00% | -20.0% |
| Q4 2015 | $2,086,000 | +47.9% | 30,893 | +1.6% | 0.01% | +25.0% |
| Q3 2015 | $1,410,000 | -5.2% | 30,393 | +9.7% | 0.00% | 0.0% |
| Q2 2015 | $1,488,000 | +111.1% | 27,693 | +88.4% | 0.00% | +100.0% |
| Q1 2015 | $705,000 | +21.6% | 14,700 | -2.0% | 0.00% | +100.0% |
| Q4 2014 | $580,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |